π FDA Pushes Lipfendra as CNPV Pilot Star
The FDA is positioning Lipfendra as a prime example for the CNPV pilot program. Merck is actively mapping out the long-term strategy for its first PCSK9 pill. This development is significant for cardiovascular drug development. The focus is on solidifying the regulatory path for these innovative medications. Further updates on the rollout are expected in the coming fiscal quarters.